Showing results (41-50 of 192) with videos related to

Sort By:
Pageof 20
Hematology. American Society of Hematology. Education Program|November 25, 2003
Myelodysplastic syndromeGhulam Mufti, Alan F List, Steven D Gore, et al.
Leukemia Research|August 20, 2011
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromesBenjamin M Craig, Dana E Rollison, Alan F List, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2004
Myelodysplastic syndromesAlan F List, James Vardiman, Jean-Pierre J Issa, et al.
Blood|May 3, 2011
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registriesChristopher R Cogle, Benjamin M Craig, Dana E Rollison, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Underreporting of myeloid malignancies by United States cancer registriesBenjamin M Craig, Dana E Rollison, Alan F List, et al.
Leukemia Research|November 25, 2016
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Antonio Almeida, Pierre Fenaux, Alan F List, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic SyndromesMintallah Haider, Eric J Duncavage, Khalid F Afaneh, et al.
Experimental Hematology|June 9, 2004
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cellsAlan F List, Betty Glinsmann-Gibson, Chad Stadheim, et al.
British Journal of Haematology|November 20, 2012
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growthLori N Griner, Kathy L McGraw, Joseph O Johnson, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2017
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic SyndromeSusmitha Apuri, Najla Al Ali, Eric Padron, et al.
Pageof 20